Susceptibility to metanephric apoptosis in bradykinin B2 receptor null mice via the p53-Bax pathway

American Journal of Physiology - Renal Physiology

Volumn 291, Issue 3, 2006, Pages

  Fan, Hao ^a   Stefkova, Jana ^a   El Dahr, Samir S ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Kallikrein kinin system; Kidney development; Ureteric bud branching

Indexed keywords

BRADYKININ B2 RECEPTOR; PROTEIN BAX; PROTEIN P53; SERINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; EMBRYO; GENE DELETION; GENE EXPRESSION; GENE INTERACTION; GENE MUTATION; GENE REPRESSION; KIDNEY; KIDNEY DEVELOPMENT; KIDNEY DYSPLASIA; MOUSE; NEPHRON; NEWBORN; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SALT STRESS; URETER;

EID: 33748419640     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00037.2006     Document Type: Article

References (48)

1. Alfie ME, Sigmon DH, Pomposiello SI, and Carretero OA. Effect of high salt intake in mutant mice lacking bradykinin-B2 receptors. Hypertension 29: 483-487, 1997.
2. Bartek J and Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3: 421-429, 2003.
3. Bates CM. Kidney development: regulatory molecules crucial to both mice and men. Mol Genet Metab 71: 391-396, 2000.
4. Blomqvist SR, Vidarsson H, Fitzgerald S, Johansson BR, Ollerstam A, Brown R, Persson AE, Bergstrom GG, and Enerback S. Distal renal tubular acidosis in mice that lack the forkhead transcription factor Foxi1. J Clin Invest 113: 1560-1570, 2004.
5. Bode AM and Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4: 793-805, 2004.
6. Borkowski JA, Ransom RW, Seabrook GR, Trumbauer M, Chen H, Hill RG, Strader CD, and Hess JF. Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J Biol Chem 270: 13706-13710, 1995.
7. Bouchard M. Transcriptional control of kidney development. Differentiation 72: 295-306, 2004.
8. 2 receptor null mice. Hypertension 34: 176-180, 1999.
9. Chavez-Reyes A, Parant JM, Amelse LL, de Oca Luna RM, Korsmeyer SJ, and Lozano G. Switching mechanisms of cell death in mdm2-and mdm4-null mice by deletion of p53 downstream targets. Cancer Res 63: 8664-8669, 2003.
10. El-Dahr SS. Spatial expression of the kallikrein-kinin system during nephrogenesis. Histol Histopathol 19: 1301-1310, 2004.
11. El-Dahr SS, Dipp S, and Baricos WH. Bradykinin stimulates the ERK→Elk-1→Fos/AP-1 pathway in mesangial cells. Am J Physiol Renal Physiol 275: F343-F352, 1998.
12. El-Dahr SS, Dipp S, Yosipiv IV, and Carbini LA. Activation of kininogen expression during distal nephron differentiation. Am J Physiol Renal Physiol 275: F173-F182, 1998.
13. El-Dahr SS, Figueroa CD, Gonzalez CB, and Muller-Esterl W. Ontogeny of bradykinin B2 receptors in the rat kidney: implications for segmental nephron maturation. Kidney Int 51: 739-749, 1997.
14. El-Dahr SS, Harrison-Bernard LM, Dipp S, Yosipiv IV, and Meleg-Smith S. Bradykinin B2 null mice are prone to renal dysplasia: gene-environment interactions in kidney development. Physiol Genomics 3: 121-131, 2000.
15. Fan H, Harrell JR, Dipp S, Saifudeen Z, and El-Dahr SS. A novel pathological role of p53 in kidney development revealed by gene-environment interactions. Am J Physiol Renal Physiol 288: F98-F107, 2005.
16. Godley LA, Kopp JB, Eckhaus M, Paglino JJ, Owens J, and Varmus HE. Wild-type p53 transgenic mice exhibit altered differentiation of the ureteric bud and possess small kidneys. Genes Dev 10: 836-850, 1996.
17. Harris SL and Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 24: 2899-2908, 2005.
18. Harrison-Bernard LM, Dipp S, and El-Dahr SS. Renal and blood pressure phenotype in 18-mo-old bradykinin B2R(-/-)CRD mice. Am J Physiol Regul Integr Comp Physiol 285: R782-R790, 2003.
19. 1 receptor in adult rat kidney using a monoclonal antibody. Am J Physiol Renal Physiol 273: F170-F177, 1997.
20. Igarashi P, Shao X, McNally BT, and Hiesberger T. Roles of HNF-1β in kidney development and congenital cystic diseases. Kidney Int 68: 1944-1947, 2005.
21. Igarashi P and Somlo S. Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol 13: 2384-2398, 2002.
22. Jin Z and El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther 4: 139-163, 2005.
23. Kim YM, Talanian RV, and Billiar TR. Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms. J Biol Chem 272: 31138-31148, 1997.
24. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, and Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57: 27-77, 2005.
25. Madeddu P, Varoni MV, Palomba D, Emanueli C, Demontis MP, Glorioso N, Dessi-Fulgheri P, Sarzani R, and Anania V. Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene. Circulation 96: 3570-3578, 1997.
26. Mannick JB, Miao XQ, and Stamler JS. Nitric oxide inhibits Fas-induced apoptosis. J Biol Chem 272: 24125-24128, 1997.
27. Marks J, Saifudeen Z, Dipp S, and El-Dahr SS. Two functionally divergent p53-responsive elements in the rat bradykinin B2 receptor promoter. J Biol Chem 278: 34158-34166, 2003.
28. Michael D and Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 13: 49-58, 2003.
29. Mills AA. p53: Link to the past, bridge to the future. Genes Dev 19: 2091-2099, 2005.
30. Mukhin YV, Garnovsky EA, Ullian ME, and Garnovskaya MN. Bradykinin B2 receptor activates extracellular signal-regulated protein kinase in mIMCD-3 cells via epidermal growth factor receptor transactivation. J Pharmacol Exp Ther 304: 968-977, 2003.
31. Murphy KM, Streips UN, and Lock RB. Bax membrane insertion during Fas(CD95)-induced apoptosis precedes cytochrome c release and is inhibited by Bcl-2. Oncogene 18: 5991-5999, 1999.
32. Nakai S, Sugitani Y, Sato H, Ito S, Miura Y, Ogawa M, Nishi M, Jishage K, Minowa O, and Noda T. Crucial roles of Brn1 in distal tubule formation and function in mouse kidney. Development 130: 4751-4759, 2003.
33. Pachnis V, Mankoo B, and Costantini F. Expression of the c-ret proto-oncogene during mouse embryogenesis. Development 119: 1005-1017, 1993.
34. Prives C and Manley JL. Why is p53 acetylated? Cell 107: 815-818, 2001.
35. Saifudeen Z, Dipp S, and El-Dahr SS. A role for p53 in terminal epithelial cell differentiation. J Clin Invest 109: 1021-1030, 2002.
36. Saifudeen Z, Dipp S, Fan H, and El-Dahr SS. Combinatorial control of the bradykinin B2 receptor promoter by p53, CREB, KLF-4, and CBP: implications for terminal nephron differentiation. Am J Physiol Renal Physiol 288: F899-F909, 2005.
37. Saifudeen Z, Du H, Dipp S, and El-Dahr SS. The bradykinin type 2 receptor is a target for p53-mediated transcriptional activation. J Biol Chem 275: 15557-15562, 2000.
38. Saifudeen Z, Marks J, Du H, and El-Dahr SS. Spatial repression of PCNA by p53 during kidney development. Am J Physiol Renal Physiol 283: F727-F733, 2002.
39. Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, and Pachnis V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 367: 380-383, 1994.
40. Schuler M and Green DR. Transcription, apoptosis and p53: catch-22. Trends Genet 21: 182-187, 2005.
41. Thornborrow EC, Patel S, Mastropietro AE, Schwartzfarb EM, and Manfredi JJ. A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine bax genes. Oncogene 21: 990-999, 2002.
42. Vainio S and Lin Y. Coordinating early kidney development: lessons from gene targeting. Nat Rev Genet 3: 533-543, 2002.
43. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, Liu J, Zhao XD, Chew JL, Lee YL, Kuznetsov VA, Sung WK, Miller LD, Lim B, Liu ET, Yu Q, Ng HH, and Ruan Y. A global map of p53 transcription-factor binding sites in the human genome. Cell 124: 207-219, 2006.
44. Woolf AS, Price KL, Scambler PJ, and Winyard PJ. Evolving concepts in human renal dysplasia. J Am Soc Nephrol 15: 998-1007, 2004.
45. q- and Gβγ-dependent pathway that involves phosphoinositide 3-kinase and Akt. J Biol Chem 275: 24907-24914, 2000.
46. Yamaguchi M, Hayashi Y, Matsuoka S, Takahashi T, and Matsukage A. Differential effect of p53 on the promoters of mouse DNA polymerase beta gene and proliferating-cell-nuclear-antigen gene. Eur J Biochem 221: 227-237, 1994.
47. Yin C, Knudson CM, Korsmeyer SJ, and Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385: 637-640, 1997.
48. Yin H, Chao L, and Chao J. Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-glycogen synthase kinase-3 and Akt-Bad 14-3-3 signaling pathways. J Biol Chem 280: 8022-8030, 2005.